Evidence review
FDA Warning Letters to GLP-1 Telehealth: The Record, and How to Check Any Provider
The FDA has issued three waves of warning letters over compounded GLP-1 marketing in under a year — roughly 80 in September 2025, 30 on 20 February 2026, and 25 on 8 June
The FDA has issued three waves of warning letters over compounded GLP-1 marketing in under a year — roughly 80 in September 2025, 30 on 20 February 2026, and 25 on 8 June 2026. The database is public and searchable, so this is one of the few provider checks a reader can complete in about two minutes. This page explains what gets cited and how to run the search.
The enforcement record
| Wave | Letters | What was cited |
|---|---|---|
| September 2025 | ~80 warning, 40 untitled | Advertising implying compounded GLP-1s were equivalent to their approved counterparts. Reported as part of a broader push that also covered compounded sildenafil and tadalafil |
| 20 February 2026 | 30 | Website claims about compounded semaglutide and tirzepatide, including marketing them as generic alternatives to Wegovy and Zepbound. Announced 3 March; 15 business days to correct |
| 8 June 2026 | 25 | False or misleading claims about compounded semaglutide, tirzepatide and, in one case, liraglutide. Posted 16 June alongside a new FDA GLP-1 webpage |
Three waves in under a year, all aimed principally at telehealth marketing rather than at compounding itself. The distinction matters: these letters are about what companies say, not about whether they may compound.
The test the FDA applies
The framework is misleading net impression. The agency assesses whether marketing taken as a whole could cause a consumer to believe a compounded product is FDA-approved, FDA-reviewed, or equivalent in any way to an approved drug — whether that is stated outright or merely implied.
That is a higher bar than avoiding false statements. A page can be literally accurate line by line and still fail, if the impression it leaves is that you are buying the approved drug more cheaply.
What specifically got cited
| Company | What the FDA objected to |
|---|---|
| Altru Telehealth | “FDA approved active ingredient”, “same results”, and “FDA approved” compounding-pharmacy claims. Also website language stating a compounded semaglutide included “a body safe vitamin such as B12” |
| Glow Medispa | Product images whose labels named the telehealth company, which the FDA said implied it was the compounder when it was not |
| Ready Med | The same issue: product images carrying the company's own name on the pictured label |
We publish a page on what is actually in a compounded GLP-1, covering the B12 additives many compounders use and the 2026 finding that tirzepatide compounded with B12 can chemically bond into a molecule not present in the approved drug.
The Altru letter shows the regulator has now objected to the marketing side of the same thing. Describing an added vitamin as “body safe” is itself a claim the FDA has cited. The additive is not a neutral bonus; it is an unstudied change to the preparation, and calling it safe is an assertion nobody has evidence for.
Two substances the FDA says may not be compounded at all
Alongside the June letters, the FDA published a GLP-1 webpage stating its position that retatrutide and cagrilintide may not be used in compounding.
That is worth knowing because both appear in consumer discussion as next-generation options, and retatrutide in particular has produced striking trial numbers. If a provider offers either as a compounded preparation, that is not a grey area.
The same webpage covers import alerts intended to keep active ingredients with quality concerns out of the United States, dosing concerns, counterfeit versions of brand-name GLP-1s, and adverse event reporting.
How to check any provider yourself, in about two minutes
- Search the FDA warning letter database for the company name.
- Search the parent company too. Telehealth brands often trade under a name different from the entity that would receive a letter, and searching only the brand can produce a false clear.
- Search the compounding pharmacy separately, if the provider has named one. This is the check most people cannot run, because most providers do not name their pharmacy — see our disclosure register.
- Note the date. A letter from 2025 that was corrected is a different thing from an open one.
What a warning letter does and does not mean
It does mean the FDA has identified conduct it considers a violation and has asked for correction within 15 business days.
It does not mean the medication is contaminated, the pharmacy is unlicensed, or the company is operating illegally in some broader sense. Almost all of these letters concern advertising. A company can receive one for a sentence on a landing page while dispensing exactly what it says it dispenses.
The absence of a letter does not mean much either. The FDA cannot review every site, and these waves are sampled rather than exhaustive. A clear search is weak evidence, not a clean bill of health.
The parallel private enforcement
Manufacturers have run their own campaign alongside the FDA's. On 9 February 2026 Novo Nordisk sued Hims & Hers for infringing US Patent No. 8,129,343 with its compounded semaglutide products, alleging the company continued to mass-compound injectable versions made with inauthentic active ingredient. Novo Nordisk has been reported to have filed more than 130 suits across 40 states.
For a patient, litigation risk is a supply risk. A provider that loses a case or settles may stop offering a product with little notice, which is a reason to read cancellation and refund terms before a prepaid plan.
What we have not done
We have not run this search against every provider in our dataset and published the results. That is a real piece of work rather than a lookup, because it requires establishing each company's legal entity first, and a wrong result in either direction would be worse than none.
We are recording it as an open task rather than implying we have done it. One publication we read states it verified a specific provider against the database on a named date — that is the right standard, and it is the standard we have not yet met.
| Field | Detail |
|---|---|
| Status | Open Verified |
| Time remaining | 4 days remain. Comments must be submitted by 2026-07-30. Anyone may comment: patients, clinicians, pharmacies and the public. Late filings are not considered. |
| What is proposed | Excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, on a finding of no clinical need |
| Notice | 91 FR 23431, published 1 May 2026 |
| Original deadline | 29 to 30 June 2026, a 60-day period |
| Extended deadline | 2026-07-30, following a request for a 60-day extension |
| Who it binds | 503B outsourcing facilities. Section 503A patient-specific compounding is a separate pathway and is not addressed |
| Shortage pathway | Unchanged: 503B facilities may still compound during a declared shortage |
| How to comment | Through the federal docket, or in writing to the contact of record at CDER |
| Contact of record | Tracy Rupp, Center for Drug Evaluation and Research, [email protected] |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Search intent match | Does the page answer the question actually being asked? |
| 2 | Original value test | What exists here that is not already on ten other sites? |
| 3 | Source and evidence review | Every claim resolves to a ledger entry with a capture date. |
| 4 | Medical review | A named clinician checks claims against their primary sources. |
| 5 | Pricing verification | Figures re-captured from the provider's own page, dated. |
| 6 | Conflict-of-interest review | Any relationship that could bias the page, declared. |
| 7 | Legal and regulatory language | No implied approval, no generic claim, no individual advice. |
| 8 | Accessibility review | WCAG 2.2 AA, keyboard, contrast, chart data tables. |
| 9 | Mobile QA | 390px viewport hides no fee, qualifier, status or date. |
| 10 | Structured-data validation | JSON-LD matches what a reader can see. |
| 11 | Internal-link validation | Parent hub, methodology, siblings, tool or dataset. |
| 12 | Duplication and cannibalisation check | No two pages chasing the same intent. |
| 13 | Date and cadence assignment | Review dates set from real work, not from the calendar. |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Questions readers actually ask
Has the FDA sent warning letters to GLP-1 telehealth companies?
Yes, in three waves in under a year: roughly 80 warning letters plus 40 untitled letters in September 2025, 30 on 20 February 2026, and 25 on 8 June 2026.
What do the warning letters actually cite?
Almost all concern advertising. The framework is misleading net impression: whether marketing as a whole could lead a consumer to believe a compounded product is FDA-approved or equivalent to an approved drug.
Can I check whether my provider has received one?
Yes. The FDA warning letter database is public and searchable. Search the brand and the parent company, since telehealth brands often trade under a different legal entity.
Does a warning letter mean the medication is unsafe?
No. These letters overwhelmingly concern what companies say rather than what they dispense. Equally, the absence of a letter is weak evidence, since the FDA samples rather than reviewing every site.
Can retatrutide or cagrilintide be compounded?
The FDA has published its position that they may not be used in compounding.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- FDA Compounded GLP-1 Rules in 2026Journal
- Medical and Regulatory DisclaimerCore & Trust
- Tirzepatide Telehealth in PennsylvaniaStates
- Tirzepatide Telehealth in OregonStates
- Tirzepatide Telehealth in OklahomaStates
- Tirzepatide Telehealth in OhioStates
- Tirzepatide Telehealth in North DakotaStates
Related coverage
Tirzepatide Ranked. “FDA Warning Letters to GLP-1 Telehealth: The Record, and How to Check Any Provider.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/fda-warning-letters/
Quote the capture date beside a figure, not the date you read this page. Why.